Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that accounts for 10-20% of all breast tumors. This comprehensive meta-analysis of nine randomized controlled trials involving 2,109 patients examined whether adding platinum-based chemotherapy drugs (carboplatin or cisplatin) to standard neoadjuvant chemotherapy (treatment given before surgery) improves outcomes for TNBC patients. The researchers found that platinum-based regimens significantly increased the rate of pathological complete response (pCR) from 37.0% to 52.1% (OR 1.96, 95% CI 1.46–2.62, P<0.001), meaning more patients had no residual invasive cancer at the time of surgery. However, this benefit came at the cost of significantly higher rates of serious hematological side effects, including neutropenia, anemia, and thrombocytopenia. Notably, the benefit was not observed in patients with BRCA gene mutations, and no significant improvement in event-free survival or overall survival was demonstrated.
Triple-negative breast cancer (TNBC) is a particularly challenging form of breast cancer that accounts for approximately 10%–20% of all breast tumors. Unlike other breast cancer subtypes, TNBC cells do not have receptors for estrogen, progesterone, or the HER2 protein—hence the name "triple-negative." This means that hormone therapies and HER2-targeted treatments that work well for other breast cancer types are not effective for TNBC patients.
Despite its aggressive behavior, TNBC has a unique characteristic that researchers call the "triple negative paradox": it is particularly sensitive to cytotoxic (cell-killing) chemotherapy. In the neoadjuvant setting—meaning chemotherapy given before surgery to shrink tumors—TNBC patients show higher response rates compared to women with hormone receptor-positive breast cancer. Approximately 30%–40% of TNBC patients achieve a pathological complete response (pCR) after standard chemotherapy that includes anthracyclines, cyclophosphamide, and taxanes.
Achieving pCR—defined as no residual invasive tumor in both the breast and the axilla (underarm lymph nodes)—has strong prognostic value in TNBC patients, even stronger than in other breast cancer subtypes. This is why neoadjuvant chemotherapy is currently considered the preferred approach for the majority of TNBC patients with early-stage disease.
Platinum agents, specifically carboplatin and cisplatin, are cytotoxic DNA-damaging compounds that work by causing DNA strand breaks, which can lead to cell death. This mechanism makes them especially active in cancer cells with DNA repair deficiencies, such as those harboring deleterious mutations in the BRCA genes. Based on the biological rationale that TNBC cells may be particularly susceptible to DNA-damaging compounds, several trials have investigated platinum agents as a treatment option for TNBC patients.
However, the results from these studies have been mixed and controversial. According to current breast cancer guidelines at the time of this research, the addition of a platinum agent to standard neoadjuvant chemotherapy in unselected TNBC patients was not recommended, though its use could be considered in breast cancer patients with deleterious germline BRCA mutations. This meta-analysis was conducted to provide up-to-date evidence on this important and controversial topic.
This study was a systematic review and meta-analysis, which is a rigorous method of combining and analyzing results from multiple independent studies to draw stronger conclusions than any single study could provide. The researchers conducted a systematic search of the Medline and Web of Science databases, with no language or date restrictions, up to October 30, 2017.
The search strategy used the following keywords: "breast cancer," "platinum," "carboplatin," "cisplatin," "neoadjuvant," and "chemotherapy." The researchers also reviewed conference proceedings from major oncology meetings, including the European Society for Medical Oncology (ESMO) congress, the American Society of Clinical Oncology (ASCO) annual meeting, and the San Antonio Breast Cancer Symposium (SABCS), to identify relevant unpublished studies.
To be included in this meta-analysis, studies had to meet specific criteria: they had to be phase II or III randomized controlled trials (RCTs); they had to include TNBC patients who received platinum-based neoadjuvant chemotherapy in the experimental arm and platinum-free neoadjuvant chemotherapy in the control arm; and they had to have available information on pCR rates in both arms. For RCTs that included patients with breast cancer subtypes other than TNBC, only those with available results in the TNBC cohort were included.
The initial literature search returned 1,328 records. After excluding 1,316 non-relevant records, 12 potentially eligible RCTs were considered. Among these, two were updates of previously published studies and one was a secondary analysis of an already included RCT. This left nine different RCTs for inclusion in the final meta-analysis.
Two of the nine RCTs were published only in abstract form. Two RCTs conducted by the German Breast Group included both TNBC and HER2-positive breast cancer patients, and one RCT (UMIN000003355) also included hormone receptor-positive/HER2-negative breast cancer patients—for the purpose of this meta-analysis, only data pertaining to TNBC patients from these trials were considered.
A total of 2,109 TNBC patients were included in the analysis, with 1,046 (49.6%) receiving platinum-based chemotherapy and 1,063 (50.4%) receiving platinum-free chemotherapy. All but one of the RCTs used carboplatin as the platinum agent; one study used cisplatin.
The researchers calculated pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) for pathological complete response, event-free survival (EFS), overall survival (OS), and grade 3 and 4 adverse events including neutropenia, anemia, thrombocytopenia, and neuropathy. An OR greater than 1 indicates higher pCR rates in the platinum-based group, while an HR less than 1 indicates improved survival outcomes with platinum-based chemotherapy.
The study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with the PROSPERO registration number CRD42018080042.
The primary objective of this meta-analysis was to compare the activity of platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients, measured by pCR rates. The results were striking.
Overall, including all nine RCTs, 938 of 2,109 patients (44.5%) achieved a pCR after neoadjuvant treatment. Breaking this down by treatment group:
This difference was highly statistically significant (OR 1.96, 95% CI 1.46–2.62, P<0.001), meaning that patients receiving platinum-based chemotherapy were approximately twice as likely to achieve a complete pathological response. The statistical significance level of P<0.001 indicates there is less than a 0.1% chance that this finding was due to random chance.
The researchers conducted several subgroup analyses to better understand these results. In the seven RCTs (N=1,698 patients) that used anthracycline- and taxane-based chemotherapy in both treatment arms, the pCR rate was 53.9% (461 of 856) in the platinum-based group versus 39.9% (336 of 842) in the platinum-free group (OR 1.85, 95% CI 1.31–2.61, P<0.001).
In the five RCTs (N=1,234 patients) that used the same chemotherapy backbone in both groups (with or without carboplatin), the pCR rate was 54.2% (338 of 623) in the platinum-based group versus 37.1% (227 of 611) in the platinum-free group (OR 2.04, 95% CI 1.39–3.00, P<0.001).
Most importantly, in the three RCTs (N=611 patients) that used the same standard neoadjuvant chemotherapy regimen of weekly paclitaxel (with or without carboplatin) followed by anthracycline plus cyclophosphamide in both groups, the benefit of adding platinum was even more pronounced:
Sensitivity analyses confirmed that the pooled estimates were stable and did not depend on any single study. The funnel plot and Harbord's asymmetry test (P=0.282) showed no evidence of publication bias, meaning it is unlikely that studies with negative results were systematically missing from the analysis.
One of the most clinically important questions addressed by this meta-analysis was whether the benefit of platinum-based chemotherapy differs based on germline BRCA mutational status. This is particularly relevant because platinum agents are known to be especially active in cancer cells with DNA repair deficiencies, such as those with BRCA mutations.
Germline BRCA mutational status was available for 609 patients in two RCTs. A total of 96 BRCA-mutated patients were included: 50 of 291 patients (17.2%) in the GeparSixto GBG66 study and 46 of 318 patients (14.5%) in the BrighTNess trial.
Surprisingly, among BRCA-mutated patients, the addition of carboplatin was not associated with a significantly increased pCR rate:
This result was not statistically significant, meaning the researchers could not demonstrate a benefit from adding platinum in BRCA-mutated patients. However, it is important to note that the number of BRCA-mutated patients was small (only 96 total), which limits the statistical power of this analysis.
In contrast, among the 513 patients without BRCA mutations, the benefit of platinum-based chemotherapy was highly significant:
This finding is counterintuitive given the biological rationale that platinum agents should be most effective in BRCA-mutated tumors. The researchers noted that this unexpected result may be due to the small sample size of BRCA-mutated patients and the fact that the analysis was not pre-specified. It is also possible that BRCA-mutated TNBC tumors are inherently more chemosensitive, making the additional benefit of platinum less detectable.
While pCR rates are an important early indicator of treatment effectiveness, the ultimate goal of cancer treatment is to improve survival. Only two RCTs (N=748 patients) reported survival outcomes in this meta-analysis.
The median follow-up was 39 months in the CALGB study and 47.3 months in the GeparSixto GBG66 study. The results for survival outcomes showed no statistically significant differences between the platinum-based and platinum-free groups:
While the HR for EFS (0.72) suggests a potential 28% reduction in the risk of events (such as cancer recurrence or death) with platinum-based chemotherapy, this result did not reach statistical significance. The confidence interval (0.49–1.06) includes 1.0, which means the true effect could range from a 51% reduction to a 6% increase in events.
The lack of significant survival benefit is an important finding. It suggests that while platinum-based chemotherapy improves pCR rates, this improvement may not translate into better long-term survival outcomes. However, the researchers noted that only two trials reported survival data, and longer follow-up from more trials is needed to draw definitive conclusions about survival benefits.
Improving pCR rates is meaningless if the treatment causes unacceptable toxicity. The researchers therefore carefully analyzed the rates of grade 3 and 4 adverse events (AEs)—the most severe side effects—in both treatment groups. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 or 4.0 was used to classify adverse events in the included RCTs.
The safety analysis revealed a significantly higher risk of hematological (blood-related) toxicities with platinum-based chemotherapy, but no increased risk of neuropathy (nerve damage). Here are the specific findings:
Seven RCTs reported rates of grade 3 and 4 neutropenia. Overall, 772 of 2,030 patients (37.8%) developed this complication:
This means patients receiving platinum-based chemotherapy were more than three times more likely to experience severe neutropenia, which increases the risk of serious infections.
Six RCTs reported rates of grade 3 and 4 anemia. Overall, 108 of 1,939 patients (5.6%) developed this complication:
Severe anemia was dramatically more common with platinum-based chemotherapy—patients were 15 times more likely to experience this side effect. Anemia can cause severe fatigue, shortness of breath, and may require blood transfusions.
Seven RCTs reported rates of grade 3 and 4 thrombocytopenia. Overall, 121 of 2,030 patients (6.0%) developed this complication:
Patients receiving platinum-based chemotherapy were more than eight times more likely to develop severe thrombocytopenia, which increases the risk of bleeding and bruising.
Six RCTs reported rates of grade 3 and 4 neuropathy. Overall, 70 of 1,937 patients (3.6%) developed this complication. Importantly, there was no significant difference between the two groups, meaning the addition of platinum agents did not increase the risk of severe nerve damage, which can cause pain, numbness, and tingling in the hands and feet.
These findings highlight an important trade-off: platinum-based chemotherapy significantly improves pCR rates but at the cost of substantially higher rates of serious blood-related side effects. Patients considering this treatment approach need to weigh these benefits and risks carefully with their healthcare team.
This meta-analysis provides the most comprehensive evidence to date on the role of platinum-based neoadjuvant chemotherapy in TNBC patients. The findings have several important implications for clinical practice and patient care.
First, the addition of platinum agents to standard neoadjuvant chemotherapy significantly increases the likelihood of achieving a pCR in TNBC patients. The absolute increase in pCR rate was approximately 15 percentage points (from 37.0% to 52.1%), which is clinically meaningful. Achieving pCR is strongly associated with better long-term outcomes in TNBC patients, making this an important goal of neoadjuvant treatment.
Second, the benefit of adding platinum appears consistent across different chemotherapy backbones, including the standard regimen of weekly paclitaxel followed by anthracycline plus cyclophosphamide. This suggests that the benefit is not limited to a specific chemotherapy combination.
Third, the finding that BRCA-mutated patients did not appear to benefit from platinum addition is surprising and clinically relevant. While this may be due to the small number of BRCA-mutated patients in the analysis, it challenges the assumption that platinum agents are particularly beneficial in this population. Patients with BRCA mutations should discuss this finding with their oncologists, as the decision to add platinum should be individualized.
Fourth, the lack of significant improvement in event-free and overall survival is a cautionary note. While pCR rates improved, this did not translate into statistically significant survival benefits in the two trials that reported these outcomes. However, the trend toward improved EFS (HR 0.72) is encouraging and may become significant with longer follow-up and more data.
Finally, the significantly higher rates of hematological toxicities—particularly anemia (15 times higher risk) and thrombocytopenia (8 times higher risk)—must be carefully considered. These side effects are manageable but may require additional treatments such as growth factors, blood transfusions, or dose reductions, and can significantly impact a patient's quality of life during treatment.
While this meta-analysis provides valuable evidence, it is important to understand its limitations. The researchers acknowledged several important constraints in their analysis.
First, there was significant heterogeneity among the included trials. The I² statistic—which measures the degree of inconsistency in results across studies—was 56.3% for the overall pCR analysis, indicating moderate to substantial heterogeneity. This means the trials differed in ways beyond random chance, which could include differences in patient populations, chemotherapy regimens, and study designs.
Second, only two RCTs reported survival outcomes, limiting the statistical power to detect differences in EFS and OS. The confidence intervals for both survival endpoints were wide, meaning the true effects could be larger or smaller than observed.
Third, the analysis of BRCA-mutated patients was based on only 96 patients from two trials, which limits the reliability of this subgroup analysis. The finding that BRCA-mutated patients did not benefit from platinum addition should be interpreted with caution.
Fourth, two RCTs did not report the specific rates of grade 3 and 4 adverse events in the two treatment arms, and two RCTs were published only in abstract form, which may limit the completeness of the safety data.
Fifth, the analysis of adverse events in two trials (GeparSixto GBG66 and UMIN000003355) included data from all patients in those trials, not just TNBC patients, under the assumption that the risk of adverse events would not be influenced by hormone receptor status. This could potentially introduce bias into the safety analysis.
Finally, the median follow-up in the survival analyses was relatively short (39 and 47.3 months), and longer follow-up may reveal different survival outcomes.
Based on the findings of this meta-analysis, the researchers concluded that platinum-based neoadjuvant chemotherapy may be considered an option in TNBC patients. However, the decision to add a platinum agent should be made on an individual basis, taking into account the potential benefits and risks.
If you are a TNBC patient considering neoadjuvant chemotherapy, here are some key points to discuss with your oncology team:
Remember that every patient is unique, and treatment decisions should always be made in close consultation with your oncology team, who can provide personalized recommendations based on your specific circumstances.
Triple-negative breast cancer (TNBC) lacks receptors for estrogen, progesterone, and HER2, so hormone and HER2-targeted therapies are ineffective. Chemotherapy before surgery, called neoadjuvant chemotherapy, is preferred because TNBC is particularly sensitive to it, and achieving a pathological complete response (no tumor left) is strongly linked to better long-term outcomes.
In the two trials that reported survival, there was no statistically significant improvement in event-free survival or overall survival with platinum-based chemotherapy. The trend suggested a possible 28% reduction in events, but this was not conclusive. Longer follow-up and more trials are needed to determine if the improved complete response rates translate into better survival.
Surprisingly, in this analysis of 96 BRCA-mutated patients, adding carboplatin did not significantly increase the complete response rate (58.0% vs 54.3%). However, the number of patients was small, so this finding is not definitive. Discuss your individual situation with your oncologist, as the decision to add platinum should be personalized.
Adding platinum significantly increases the risk of severe blood-related side effects: neutropenia (low white blood cells) is 3 times more likely, anemia (low red blood cells) is 15 times more likely, and thrombocytopenia (low platelets) is 8 times more likely. However, it does not increase the risk of severe neuropathy (nerve damage). These side effects are manageable but may require extra treatments.
The benefit was consistent across different chemotherapy backbones. In the three trials using the standard regimen of weekly paclitaxel followed by anthracycline plus cyclophosphamide, the complete response rate improved from 33.3% to 54.9% with the addition of carboplatin. This suggests the benefit is not limited to a specific combination.
Yes, discuss the potential benefits and risks. Adding platinum can increase your chance of a complete response from about 37% to 52%, but it also raises the risk of severe blood-related side effects. Your oncologist can help you weigh these factors based on your tumor characteristics, BRCA status, overall health, and personal preferences.
Original Article Title: Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer- a systematic review and meta-analysis
Authors: F. Poggio, M. Bruzzone, M. Ceppi, N.F. Pondé, G. La Valle, L. Del Mastro, E. de Azambuja, and M. Lambertini
Journal: Annals of Oncology, Volume 29, Issue 7, pages 1497–1508, 2018
DOI: 10.1093/annonc/mdy127
Published: Online June 4, 2018
PROSPERO Registration: CRD42018080042
This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Always consult with your healthcare provider about treatment decisions.
Use collapsible tabs for more detailed information that will help customers make a purchasing decision.
Ex: Shipping and return policies, size guides, and other common questions.